In addition, double-expressor lymphoma, defined as overexpression of MYC and BCL2 proteins without chromosomal rearrangements, although not a distinct WHO classification, accounts for 20–30% of DLBCL cases and also has poor outcomes13. Here, BCL2 is linked to diffuse large B-cell lymphoma.